Study Oversight Implications of ICH GCP E6(R3) for Outsourced Sponsors

This white paper examines the implications of the ICH GCP E6(R3) guidelines for sponsors who outsource their clinical trials. It outlines key changes introduced by the new guidelines, emphasizing the importance of a proactive, risk-based approach to trial oversight. The paper details the necessity for sponsors to adapt their oversight processes to ensure compliance and maintain data quality. It discusses the shift from focusing solely on essential documents to essential records, which includes a broader range of information. The white paper also highlights the challenges faced by sponsors in maintaining oversight, including the need for direct access to essential records and the importance of documenting decision-making processes. Additionally, it addresses the increased training requirements for personnel involved in clinical trials and the barriers to effective oversight, such as process and technology challenges. The findings are based on insights from a cross-industry working group of sponsors and CROs, aiming to facilitate a smooth transition to the new guidelines.